Smartway Pharmaceuticals and Ambrose Healthcare agree early access programmes

Ambrose Healthcare and Smartway Pharmaceuticals announced today that they have signed an agreement for the provision of international Early Access Programmes for future Ambrose products.

Under this agreement, Smartway Pharmaceuticals will provide compliant distribution of Ambrose Healthcare therapeutics under international early access, compassionate use and named patient supply provisions.

Josh Cocklin, Chief Executive of Smartway said: “Ambrose is embarking on an ambitious journey to develop important medicines for rare conditions and we are pleased to help them in their quest. It’s exciting for us to find an experienced and commercially-focused company that shares our patient centred mission to “transform lives by empowering access to medicines globally.”

Toby Wilson Waterworth, Chair of Ambrose added: “We are delighted to work with Smartway. They have built an impressive team with the necessary regulatory and other experience and expertise to help specialist companies like Ambrose develop global, early or expanded access programs. We will lock into their global regulatory expertise and global distribution coverage. The most important thing for us was to find a partner who wanted to work with us to develop the programmes and add capability to our team. Smartway have shown that this is what they do and how they work.”

This latest deal extends Ambrose Healthcare’s collaborative approach, which is establishing an international network of expertise from asset acquisition, product launch, to revenue generation and sales.

About Smartway Pharmaceuticals (www.smartwaypharma.com)

Smartway Pharmaceuticals designs, implements and manages global Early / Expanded Access Programs. We partner with pharma and biotechs who trust Smartway as a leader in the provision of Expanded Access, Early Access, Compassionate Use and Named Patient Programs across 98 countries.

Over the last 20 years, Smartway have gained the experience it takes to strategically advise, design, initiate and manage global or regional programs with biotechs and pharma to empower patient access to medicines. As part of its specialist offering, Smartway provide end-to-end solutions to manage complex EAPs, whatever the size and scale. https://www.smartwaypharma.co.uk/how-we-help/eap

About Ambrose Healthcare (www.ambrosehc.com)

Ambrose Healthcare is a specialist pharmaceutical company with ambitious plans to address unmet medical needs in rare disease. The company will provide treatments for hospitals or specialist care.The US National Institutes of Health (NIH) lists more than 7,000 rare diseases[1], affecting around 400 million people worldwide[2] a $195bn market (2022) growing at 8.5% pa[4]. However, the US FDA reports that only 600 drugs have been approved in rare disease, as of 2020[3].Ambrose is developing a portfolio of commercial and clinical-stage therapeutic assets through acquisition, licensing and collaborations.

References:

1. U.S. National Institutes of Health (rarediseases.info.nih.gov/about)

2. CamRARE – Cambridge Rare Disease Network (www.camraredisease.org/)

3. National Organization for Rare Disorders (rarediseases.org/new-study-investigates-the-number-of-available-orphan-products-generics-and-biosimilars/

4. GMI Insights (www.gminsights.com/industry-analysis/rare-disease-treatment-market)